Environmentally Sustainable Health Systems in Canada

https://policybase.cma.ca/link/policy14489

POLICY TYPE  Policy document
DATE        2022-10-22
TOPICS      Population health, health equity, public health
            Health systems, system funding and performance

Documents

---

CMA POICY

Environmentally Sustainable Health Systems in Canada

RATIONALES

The Canadian Medical Association (CMA) supports the development of environmentally sustainable healthcare systems in Canada. These systems should address the need for universal healthcare, promote health equity, and incorporate principles of sustainable development. This policy document outlines the rationale for supporting such systems.

Healthcare facilities and systems are significant contributors to environmental degradation, consuming large amounts of resources and generating substantial waste. To achieve sustainability, healthcare systems must adopt strategies that reduce their environmental impact while maintaining high-quality care. This includes the use of renewable energy sources, waste reduction programs, and sustainable procurement practices.

The CMA encourages healthcare providers and policymakers to consider the following aspects when developing environmentally sustainable healthcare systems:

1. Energy Efficiency: Investing in energy-efficient technologies and systems can significantly reduce the carbon footprint of healthcare facilities. This includes the use of renewable energy sources such as solar or wind power.
2. Waste Reduction: Implementing waste reduction programs, such as recycling and composting, can help minimize the environmental impact of healthcare operations.
3. Sustainable Procurement: Purchasing supplies and medical equipment from environmentally responsible sources can reduce the environmental footprint of healthcare systems.
4. Sustainable Transportation: Encouraging the use of electric or hybrid vehicles for transportation can help reduce greenhouse gas emissions.
5. Water Conservation: Implementing water-saving technologies and practices can help conserve water resources and reduce the environmental impact of healthcare operations.
6. Sustainable Education and Training: Educating healthcare professionals about environmental sustainability can help create a culture of sustainability within healthcare systems.

These strategies should be integrated into the planning and operation of healthcare systems to ensure that they are environmentally sustainable and equitable. The CMA supports the development and implementation of policies and programs that promote the integration of sustainability into healthcare systems.
CMA 2023 Pre-budget Submission to the House of Commons Standing Committee on Finance
https://policybase.cma.ca/link/policy14490

POLICY TYPE: Parliamentary submission
DATE: 2022-10-06
TOPICS:
- Health systems, system funding and performance
- Health human resources
- Population health, health equity, public health

Documents
CMA Recommendations on Canada’s First National Adaptation Strategy: Addressing the health impacts of climate change
https://policybase.cma.ca/link/policy14484

POLICY TYPE: Parliamentary submission
DATE: 2022-06-23
TOPICS: Population health, health equity, public health
        Health systems, system funding and performance

Documents
CMA Recommendations on Vaccine Equity and Intellectual Property

https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

https://policybase.cma.ca/link/policy14474

POLICY TYPE
Parliamentary submission

DATE
2022-05-03

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents

Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

Dr. Alka Lamba
President-Elect of the Canadian Medical Association

May 4, 2022

[Signature]
New Criminal Code offence to protect health workers from threats and violence, including online
https://policybase.cma.ca/link/policy14463

POLICY TYPE
Parliamentary submission

DATE
2021-11-16

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
The Lancet Countdown on Health and Climate Change – Policy brief for Canada, October 2021
https://policybase.cma.ca/link/policy14455

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Policy endorsement</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2021-10-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

**Documents**
São Paulo Declaration on Planetary Health
https://policybase.cma.ca/link/policy14456

POLICY TYPE
Policy endorsement

DATE
2021-10-04

TOPICS
Population health, health equity, public health

Documents
Vaccine certificates

https://policybase.cma.ca/link/policy14448

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
Mandatory COVID-19 vaccination of health care workers

https://policybase.cma.ca/link/policy14449

POLICY TYPE  Policy document

DATE     2021-08-21

TOPICS
Health human resources
Population health, health equity, public health
Vaccine acceptance

https://policybase.cma.ca/link/policy14450

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Global vaccine equity

https://policybase.cma.ca/link/policy14451

POLICY TYPE  Policy document
DATE  2021-08-21
TOPICS  Ethics and medical professionalism
  Population health, health equity, public health

Global vaccine equity

Policy recommendation:
1. Strong encouragement to ensure access to vaccines. The World Health Organization should be supported to ensure equitable access to vaccines worldwide.
2. Strengthening the global supply chain to enhance vaccine distribution.
3. Implementing measures to ensure vaccine equity, including financial support for vulnerable populations.
4. Advocating for increased collaboration between governments, international organizations, and private entities to address vaccine shortages.

Support:
- The Canadian Medical Association (CMA) has been advocating for global vaccine equity and access.
- The World Health Organization (WHO) is working to ensure equitable distribution of vaccines.

Policies:
- Canada has committed to donating vaccines to countries in need.
- The CMA has called for priority vaccination of high-risk populations.

Conclusion:
The CMA supports global vaccine equity as a means to protect public health and ensure fairness in the distribution of vaccines.
Return to school during COVID-19
https://policybase.cma.ca/link/policy14452

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents

1. The CMA recommends that vaccines be used for all eligible students, as they are safe and effective. Schools should be prepared to implement vaccination programs that are consistent with public health guidelines.

2. Effective communication is essential to ensure that parents and guardians are aware of the vaccine program and its benefits. Schools should provide clear and timely information about the vaccine program and its implementation.

3. Schools should consider implementing a vaccine program that includes the following components:
   - Vaccination clinics at school
   - Parental consent for vaccination
   - Provision of information about the vaccine
   - Monitoring of vaccine efficacy

4. The CMA recommends that schools provide a supportive and inclusive environment for students who choose not to be vaccinated.

5. The CMA recommends that schools provide support and resources for students who require accommodations for medical reasons.

6. The CMA recommends that schools provide support and resources for students who require accommodations for religious reasons.

7. The CMA recommends that schools provide support and resources for students who require accommodations for personal reasons.

8. The CMA recommends that schools provide support and resources for students who require accommodations for economic reasons.

9. The CMA recommends that schools provide support and resources for students who require accommodations for social reasons.

10. The CMA recommends that schools provide support and resources for students who require accommodations for educational reasons.
Interchangeability of vaccines (vaccine mixing)

Policy document

2021-08-21

Health care and patient safety
Population health, health equity, public health

Interchangeability of vaccines (vaccine mixing)

Policy position recommendation:
1. The CMA recommends the immediate implementation of guidelines for the interchangeability of vaccines. The guidelines should be based on the best available evidence and international practice.

2. The CMA recommends that health authorities consider the use of the AstraZeneca/Oxford vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

3. The CMA recommends that health authorities consider the use of the Johnson & Johnson vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

4. The CMA recommends that health authorities consider the use of the Moderna vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

5. The CMA recommends that health authorities consider the use of the Novavax vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

6. The CMA recommends that health authorities consider the use of the Sinopharm vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

7. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

8. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

9. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

10. The CMA recommends that health authorities consider the use of the Covaxin vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

11. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

12. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

13. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

14. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

15. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

16. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

17. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

18. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

19. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

20. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

21. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

22. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

23. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

24. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

25. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

26. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

27. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

28. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

29. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

30. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

31. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

32. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

33. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

34. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

35. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

36. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

37. The CMA recommends that health authorities consider the use of the Covishield vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

38. The CMA recommends that health authorities consider the use of the Sinovac vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

39. The CMA recommends that health authorities consider the use of the Sputnik V vaccine in a similar manner as the Pfizer/BioNTech vaccine, if appropriate, in order to achieve a consistent approach to vaccine interchangeability.

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Appearance before the House of Commons Standing Committee on Finance
Bill C-30: The Budget Implementation Act, 2021
https://policybase.cma.ca/link/policy14437

POLICY TYPE
Parliamentary submission

DATE
2021-05-20

TOPICS
Population health, health equity, public health

Documents

Appearance before the House
of Commons Standing
Committee on Finance

Bill C-30: The Budget
Implementation Act, 2021

Dr. E. Ann Collins
President of the Canadian Medical Association
May 21, 2021

[Signature and title]
Enhancing equitable access to virtual care in Canada: Principle-based recommendations for equity
https://policybase.cma.ca/link/policy14447

POLICY TYPE  Policy endorsement
DATE  2021-04-30
TOPICS  Population health, health equity, public health
  Health information and e-health

Documents